Florida International University

FIU Digital Commons
FIU Electronic Theses and Dissertations

University Graduate School

11-4-1999

A study of cartenoids uptake in human subjects and
their metabolites
Yin Chen
Florida International University

DOI: 10.25148/etd.FI14060180
Follow this and additional works at: https://digitalcommons.fiu.edu/etd
Part of the Chemistry Commons
Recommended Citation
Chen, Yin, "A study of cartenoids uptake in human subjects and their metabolites" (1999). FIU Electronic Theses and Dissertations.
2148.
https://digitalcommons.fiu.edu/etd/2148

This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in
FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.

FLORIDA INTERNATIONAL UNIVERSITY
Miami, Florida

A STUDY OF CAROTENOIDS UPTAKE IN HUMAN SUBJECTS AND THEIR
METABOLITES

A thesis submitted in partial fulfillment of the
requirements for the degree of
MASTER OF SCIENCE
in
CHEMISTRY

by

YIN CHEN

1999

To: Dean Arthur W. Herriott
College of Arts and Sciences
This thesis, written by Yin Chen, and entitled A Study of Carotenoids Uptake in Human
Subjects and Their Metabolites, having been approved in respect to style and intellectual
content, is referred to you for judgment.
We have read this thesis and recommend that it be approved.

Richard A. Bone

David Becker

John T. Landrum, Major Professor

Date of Defense: November 4, 1999
The thesis of Yin Chen is approved.

Dean Arthur W. Herriott
College of Arts and Sciences

Dean Richard L. Campbell
Division of Graduate Studies

Florida International University, 1999

DEDICATION

I dedicate this thesis to my parents, my husband and especially my two wonderful
sons, Peter and Eric. Without their patience, understanding, support, and most of all love,
the completion of this work would not have been possible.

I wish to thank my committee members: Dr. Richard A. Bone, Dr. David Becker,
and Dr. John T. Landrum for their support, patience, and good humor. Their gentle but
firm direction has been most appreciated. Dr. Richard Bone has been patiently helping
me in every detail while I was working in his lab. Dr. David Becker has given me a lot of
good suggestions. Finally, I would especially like to thank my major professor, Dr. John
T. Landrum for having the confidence in my abilities to complete this work.
And finally, I would like to thank Chritian Herrero and Mark Kilbum for assisting
me with a lot of details. I also thank all the co-workers in the lab.

ABSTRACT OF THE THESIS
A STUDY OF CAROTENOIDS UPTAKE IN HUMAN SUBJECTS AND THEIR
METABOLITES
by
Yin Chen
Florida International University, 1999
Miami, Florida
Professor John T. Landrum, Major Professor
In this study, a metabolite of lutein was tentatively shown to result from oxidation of
lutein by performing a reduction reaction. The result is important evidence that supports
the hypothesis that lutein functions as an antioxidant in the human body. In a long term of
dietary supplementary study of zeaxanthin in a human subject, the expected increase in
the serum concentration of the supplement was accompanied by an increase in serum
concentration of several metabolites. A six-month low dose dietary supplementation with
lutein in

2 2

human subjects was performed with an expected result in increase of the

serum concentration lutein and macular pigment optical densities. The mean increase of
serum lutein concentration and macular pigment optical density in all subjects are 128%
and 4.5%, respectively. The abundance of zeaxanthin stereoisomers in 18 of the subject’s
serum was also measured. We noted a significant difference in zeaxanthin stereoisomer
composition between the serum and the retina. The all-rrarcs-RR-zaexanthin was the
predominate form presented in human serum. This result is in agreement with previously
published work.
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INTRODUCTION

1.

Natural Occurrence and Distribution
Carotenoids are one of the main classes of natural pigments. Around 600 naturally

occurring carotenoids have been isolated and identified. (Straub, 1987) They are related
to the beautiful colors of many fruits (e.g. pineapples, citrus, orange, tomatoes),
vegetables (paprika, spinach and many green vegetables) and flowers (e.g. marigold,
sunflower). The greatest production of carotenoids occurs in the photosynthetic tissues of
plants, algae and bacteria. (Pfander, 1992) Although carotenoids are commonly
considered plant pigments, they also occur widely in microorganisms, such as bacteria.
Many animals are also colored by carotenoids, including birds (flamingo, ibis, canary),
insects

(ladybird)

and marine

animals

(salmon).

Significantly,

carotenoids

are

synthesized in nature only by plants and microorganisms. Animals are not able to
synthesize carotenoids. The carotenoids found in animals are derived from dietary
sources.
2.

Structures and Properties
As is well known, the carotenoid pigments belong to the class of polyenes. Most

naturally occurring carotenoids contain 40 carbon atoms, corresponding to

8

isoprene

units linked to form a conjugated double bond system. The carbon skeleton of the
carotenoids is highly branched. The acyclic hydrocarbon lycopene, (Figure 1) can be
considered as the prototype of these carotenoids. Other carotenoids can be considered to
be related to lycopene through structural changes and as oxygenated derivatives. For
example, 6 ,6 -carotene (Figure 1) can be regarded as resulting from cyclization of both

Figure 1. The structures of the most abundant carotenoids
in human body

end-groups in lycopene. The end-groups of carotenoids can form several different
structural moieties. Since the two terminal groups of carotenoids may be either identical
or different, both symmetrical and non-symmetrical carotenoid structures exist. The long,
conjugated double-bond system also offers many spatial possibilities. The double bonds
of the natural carotenoids are usually found to have an all-E (trans) geometry because
this is the most stable geometry. The oxygenated carotenoids can be alcohols, aldehydes,
ketones, or acids. Some of the most important and characteristic carotenoids are the
carotenes lycopene, 6,13-carotene, and the xanthophylls zeaxanthin, and lutein. Their
structures are shown in Figure 1. They are the most abundant carotenoids in the human
body because of their high concentration in dietary sources. (Khachik, et al., 1992A;
Barua, et al., 1992; Khachik, et al., 1992B) The function and metabolism of those
carotenoids in the human body is an area of considerable research activity.
Carotenoids have special properties due to their chemical structures. Because of
the presence of the polyene chain, the all-trans or all-E carotenoids may undergo
geometrical isomerization producing cis-or Z-isomers. A large number of geometrical
isomers is theoretically possible for any carotenoid. (Zechmeister, 1962) In general, there
are two types of double bonds in the polyene chain of most C40 carotenoids. (see Figure
2) However, the cw-geometry is sufficiently stable only for those double bonds which are
of the type A where two CH groups are adjacent. This is because there is less hindrance
from overlapping of hydrogen atoms in these bonds than those disubstituted double bonds
of type B having a hydrogen atom and a methyl group which sterically interfere. It is not
surprising that most natural carotenoids occur predominantly in the all-trans (all-E) form
because its nearly planar structure allows for effective resonance throughout the polyene.

An all-trans (all-E) carotenoid is generally expected to surpass in stability its cA-isomers
(Z-isomers). In practice, few cw-isomers o f carotenoids are encountered. Despite this lack
of stability, a few exam ples of naturally abundant cis-isomers are known, for example
natural Bixin, Figure 3.

Carotenoids are insoluble in water but are soluble in fats or in dipolar solvents.
They are sensitive to light and heat which can cause E/Z isomerization, and to air and
peroxides which can cause oxidation. In the presence o f acid they can undergo addition
reactions o f electrophiles to the carotenoid.

3.

Biological Functions
The most characteristic feature of carotenoids is their observed color, which is

caused by the conjugated polyene chain. As natural pigments, carotenoids are widely
used as additives, to provide attractive colors, in manufactured foods. Although synthetic
carotenoids are now produced on a large scale for food coloration, natural extracts are
still extensively used.
In photosynthetic systems, carotenoids have the important functions of lightharvesting and photo-protection. (Cogdell, 1985) The functions of carotenoids in
photosynthesis depend on their location and orientation relative to the other components.
In photosynthetic bacteria, carotenoids act as accessory light-harvesting pigments where
they function by transferring their excitation energy to bacteriochlorophyll through
singlet energy transfer. Studies have demonstrated that natural all-trans (E) carotenoids
are involved in this process. (Koyama et al., 1990) In plants and algae, carotenoids in the
reaction center are able to protect against photosensitized oxidation by quenching the
excitation energy of the chlorophyll triplet state and singlet oxygen.
Vitamin A deficiency is a worldwide nutritional problem. Vitamin A deficiency in
humans can cause blindness and premature death. Vitamin A also has important systemic
functions in humans related to growth, health maintenance, and development. As a
micronutrient, the best known function of carotenoids is the provitamin A activity.
(Zechmeister, 1962) Particularly 6 ,6 -carotene, but also, carotenoids with an unsubstituted
6

-ionene ring such as a-carotene, y-carotene, and p-cryptoxanthin are sources of vitamin

A. These C40 - carotenes are converted in the body into vitamin A and vitamin A
derivatives. The mechanism of the cleavage is not established. Central cleavage by a 15,

15’-dioxygenase enzyme has been proven but isolation of the enzyme has proven illusive.
Eccentric cleavage of other double bonds also occurs. (Zechmeister, 1962) The complete
nature of the conversion process is still far from clear.
Several studies have demonstrated that carotenoids act as antioxidants and may
have an important protective action against several types of cancers. (Khachik, et al.,
1995) This protective effect is not related to the formation of vitamin A. A number of
studies have shown that consuming large quantities of fruits and vegetables which
contain major dietary carotenoids such as lycopene or lutein, reduces the risk of cancer.
Lycopene and lutein have high antioxidant activity. (Khachik, et al., 1995)
The nonprovitamin A carotenoids have other biological functions and activities.
For example, Bone et al established that the macular pigment may play a protective role
in the eye. (Bone, et al., 1985; Schalch, 1992) The human macular pigment is a mixture
of two carotenoids, lutein and zeaxanthin. (Bone, et al., 1985) The most important
function of these carotenoids is to provide the central retina with protection against
damaging photochemical reactions initiated by absorption of blue light. Blue light has a
short wavelength and it can induce the formation of reactive free radicals, triplet excited
states, superoxide, and singlet oxygen within the retina. The macular pigments harmlessly
absorbs blue light reducing the potential for damage to the delicate retinal tissues. In a
recent study, Landrum et al found that the serum levels of lutein and the level of lutein in
the macula of the human eye are both increased by long-term dietary supplementation.
(Landrum, et al., 1997)
Considerable evidence supports the hypothesis that light-promoted damage to the
retina is one of several possible factors contributing to the development of Age - Related

Macular Degeneration (AMD), which occurs in about 20% of the population above the
age of 65. (Landrum, et al., 1997; Landrum, et al., 1995)
4.

Techniques used in the carotenoid analysis.
In order to accurately identify individual carotenoids, a number of techniques are

required. Because of their long, conjugated double bond system, the carotenoids exhibit a
strong absorption in the visible and UV region. The extinction coefficients of many
carotenoids have been published and are widely used. (Davies, 1976; De Ritter, et al.,
1981; Britton, 1985; and Kohler, 1995) Several important facts can be obtained from the
spectrum.
1) The wavelength of maximum absorption provides structural information. As the
length of the chromophore increases, the energy required to promote one of the
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bonding electrons to the excited state is reduced and the absorption occurs at a
longer wavelength.
2) The intensity of absorption is related to the structure. The optical density or
absorbance is a measure of the concentration of the carotenoids. The formation of
Z or c/s-isomers will cause a hypsochromic shift in ^ max and a lowered value of
the extinction coefficient results.
3) Most carotenoid spectra are characterized by three overlapping peaks. The degree
of overlap provides important information for identification. It is useful to
calculate the value of %III/II for describing fine structure. (Ill is the peak height
of the longest-wavelength absorption band/ II is that of the middle absorption
band) (Figure 4 ).

Figure 4. C om parison of the absorption spectra o f geom etrical
isom ers o f p, (3-carotene in hexane

4)

The UV spectrum also provides some information to identify E/Z or cis-

trans isomers. In addition to the hypsochromic shift in the wavelength of
m axim um absorption, Z or ds-isom ers exhibit a reduction in vibrational fine
structure and the appearance of a cis peak at a position about 142 nm below the
wavelength o f maxim um absorption. Usually the intensity of the dx-band is the
greatest when the cis double bond is closest to the center o f the molecule.
Therefore, a 15-cw isom er shows a well-developed cis-band. (Figure 4) For
conclusive identification, NM R is required.
Because o f the involvem ent of carotenoids in many biochem ical and biological
processes, num erous m ethods of isolation and detection of carotenoids have been
developed. HPLC in com bination with a number of different detectors is the current

method of choice. (Handelman, et al., 1992; Khachik, et al., 1992; and Craft, 1992))
HPLC with UV detection is the most frequently used and this method gives excellent
separation in a short time and is highly sensitive. Alternatively, HPLC can be coupled
with a multi-wavelength photodiode array detector for carotenoids analysis. (De
Leenheer, et al., 1992; and Sowell, et al., 1988) In comparision to the UV detector,
the photodiode array gives more information because complete spectra can be
obtained which can be compared with those of standards. However, photodiode
arrays are somewhat less sensitive than the conventional UV detectors and are more
expensive. Identifications are often made by simply comparing retention times of
unknown peaks with those of reference materials. However, only a limited number of
synthetic carotenoid standards are readily available. It is unwise to attempt
identifications based solely on retention time and UV spectrum since many
carotenoids have very similar structures. Therefore, HPLC-MS coupling is another
useful method. The specificity of mass spectrometric detection for identification of
carotenoids greatly improves the identification process, (van Breemen, 1996; and van
Breemen, et al., 1993)
The ds-isom ers of cartenoids are generally poorly separated from frans-isomers.
These isomers have sufficiently similar absorption coefficients such that the exact
structure is often impossible to determine by UV techniques. HPLC-MS is also of
limited usefulness for identification cis/trans isomers, all of which have the same
mass, and yield identical fragmentation patterns. The method of choice for structural
elucidation of cis/trans isomers is !H NMR spectroscopy. (Strohschein, et al., 1997)
Large quantities (typically several pg) are required for NMR. For this reason NMR is

of limited value in practice due to the low concentrations of the carotenoids found in
plants and other biological samples.
5.

Outline of experiments
In order to address some of the problems that are of interest to the scientists
working in the carotenoid field, my research work focuses on the following four
topics:

Part 1 Study of Metabolites of Carotenoids
Part 2 Zeaxanthin Supplementation Study
Part 3 A Six months study of Lutein Uptake in 22 Human Subjects
Part 4 Zeaxanthin Stereoisomers in Human Serum Samples
Each part will contain an overview, experiment procedure, results and discussion,
and conclusions.

II

PARTI

1.

Overview

STUDY OF THE METABOLITES OF CAROTENOIDS

The vitamin A activity of provitamin A carotenoids is well established. (Straub,
1987) However, the nutritional and metabolic benefits of non-provitamin A carotenoids
are still insufficiently investigated. Recently, a number of epidemiological studies have
demonstrated that a high consumption of fruits and vegetables may reduce the risk of
cancer. (Khachik, et a l, 1992; Khachik, et a l, 1995; Khachik, et a l, 1997; Khachik, et
a l, 1997) It was also reported that the chances of several types of cancer are very low in
regions where consumption of several types of fruits and vegetables on part of the normal
diet. (Khachik, et a l, 1995) It is known that lutein, which is found in human serum, is a
non-provitamin A carotenoid. (Khachik, et a l, 1992; Barua, et a l, 1992; Khachik, et a l,
1992) Although the carotenoids found in commonly consumed fruits and vegetables have
been identified, not all of them are present in human blood. It has been reported that at
least 21 carotenoids are found in blood. Seven of these are reported to be metabolites.
(Khachik, et a l, 1995) Since the concentration levels of these metabolites are very low,
their identification is very difficult. Khachik et al reported that oxidation products of
lutein, zeaxanthin, and lycopene are present in human serum. (Khachik, et a l, 1995) A
possible metabolic pathway for the oxidation of lutein in humans was proposed. A
combination of several reactions are required to account for the formation of these lutein
metabolites. An equilibrium was suggested to exist between (3R,3’R,6’R)-lutein and
(3R,3’R)-zeaxanthin and the intermediate (3R,3’S,6’R)-lutein, (3’-epilutein), as shown in

Figure 5. (Khachick, et al., 1995) Allylic oxidation of natural lutein at the allylic 3 ’
hydroxyl group and may result in the formation of oxolutein. It was suggested that the
double bond migration followed by allylic oxidation of oxoluteins would result in the
formation of mono- and di-ketocarotenoids as shown in Figure 6. (Khachick, et al., 1995)
The proposed mechanism by which carotenoids function in cancer prevention is based on
their antioxidant capability. They are able to quench singlet oxygen and react with other
oxidizing species, inhibit lipid peroxidation, and thereby prevent promotion and
replication in the neoplastic cells. Lutein is a proposed antioxidant and its oxidation
products should be found in serum.

Figure 5.

Equilibrium between lutein, 3’-Epilutein, and zeaxanthin in human
serum (Khachik, et al. 1995)

Figure 6.

Formation of diketocarotenoids from oxoluteins (Khachik, et al.
1995)

In order to identify the possible oxidation products of the carotenoids, a powerful
analytical technique, such as LC-MS is generally used. (Khachik et al., 1997) Although
HPLC coupled with a UV detector cannot give exact structural information, it is still the
most com mon m ethod for carotenoid analysis due to it high sensitivity. This method has
been used in our group for the analysis of carotenoids extracted from human serum.
Figure 7 shows a typical chrom atogram of the carotenoids found in human serum
obtained using a reversed-phase HPLC with a UV detector. Several peaks can be
identified with a high degree of confidence based upon their retention times. The most
abundant peak, which elutes at 10.958 min, is the lutein peak. Peaks at retention time
11.758, 19.575, 27.975, 77.0 and 84.90 min are identified as zeaxanthin, p-cryptoxanthin,

a-carotene and p-carotene, respectively. However, several peaks are found to be present
for which the identity is not known. Two of them, referred to as A and B, are constantly
present in the chromatograms of carotenoids extracted from human serum. These two
peaks have been found to be lutein-related. They are suspected to be oxidation products
of lutein in human serum based on the following observations. First, it has been found
that the area of these two peaks increased with increases in the lutein peak which
occurred in a long-term lutein supplementation study. (Landrum, et al., 1997) Second,
based on reports in the literature (Khachik et al., 1995), the reported oxidation products
of lutein should elute at earlier times than the hydroxycarotenoids.
The purpose of this part of this work is to further characterize these metabolites of
lutein in human serum. The results of this study will be helpful in understanding the
function of lutein as an antioxidant in human blood. The identification of the metabolites
of lutein can also helpful in determination of the total concentration of lutein in serum.
2.

Experimental

(1) Reagents and materials
Lutein and zeaxanthin were extracted from marigold flowers and guji berry,
respectively. Lutein and zeaxanthin standards were prepared at a concentration ratio of
1:1. The concentrations of lutein and zeaxanthin were determined at wavelength 451 nm
using an UV spectrometer. It is known that the molar absorption coefficient of lutein and
zeaxanthin are 144800 and 140900 L/(mol, cm) in ethanol.
HPLC grade of methanol, acetonitrile, triethylamine and hexane were purchased
from Fisher. The reduction reagent sodium borohydride (98%) was purchased from

Aldrich Chemical Company. (Milwaukee WI 53233 USA) The nitrogen gas was
purchased from Air Products and Chemical, Inc.
The blood samples were drawn from a healthy, female volunteer.
(2) Apparatus
Reversed-phase HPLC system (1) is a LDC/Milton Roy solvent delivery system
equipped with a 50 pi injection loop and it was coupled with a SM4000 UV-visible
detector set at 451 nm. The data was stored and processed by a Peak Simple computing
system.
The reversed-phase HPLC system (2) is a LDC/Milton Roy solvent delivery
system equipped with a 250 pi injection loop and it was coupled with a Shimadzu SPDM 6 A photodiode array UV/Vis detector. The wavelength scan range is set at 195-600
nm. The data was stored and processed in a Shimadzu supplied software.
A Centrific Model 228 Centrifuge was used which was purchased from Fisher. A
Fisher brand K-550-G Vortex was also used.
(3) Procedures
(i) Reduction of serum extract with NaBH 4
Serum extraction: A pair of frozen serum samples (serum samples were obtained from a
blood sample drawn from the same person on the same day) were chosen. They were left
at room temperature for 30 min to allow them to defrost and then homogenized by
shaking the sample vials gently several times to insure homogeneity of the sample. A 2
ml aliquot of serum was transferred into a 10 ml centrifuge tube by a pipette. The serum
proteins were precipitated by the addition of 2 ml of ethanol/deionized water (50:50
V:V). The carotenoids were extracted with three 4 ml portions of hexane, and followed

by a 1 min vortex and 5 min centrifugation. The hexane layer was removed by pipette
into a

2

ml high-density polypropylene vial and evaporated to dryness under a gentle

stream of nitrogen. One of the extracted carotenoid samples was treated with NaBH 4
following the reduction reaction procedures. Another extract was analyzed directly
without treatment with NaBH 4 for the purpose of the comparison. All the procedures
were preformed carefully in a dim light condition.
Reduction reaction: About 1 g NaBH 4 in 10 ml MeOH solution was prepared in a round
bottom flask.

1 0 0

pi of this solution was transferred to a high-density polypropylene vial

that contained the extracted carotenoids. The reduction reaction occurs rapidly and after a
10 min period, 1 ml of deionized water was added to decompose the excess NaBH4. The
solution obtained was carefully transferred into a 10 ml centrifuge tube with pipette. The
reduced carotenoids were extracted with three portions of 3 ml hexane and followed by 1
min vortex and 5 min centrifugation. The hexane layer was removed and dried under a
stream of nitrogen.
H PLC analysis'. Carotenoids extracted from serum with or without reduction by NaBH 4
were analyzed by the reversed-phase HPLC system (1) equipped with an SM4000 UVvisible detector set at 451 nm. The data was stored and processed using the Peak Simple
data acquisition system. The column used was a 250 x 4.6 mm Ultracarb C18 3 pm ODS
(Phenomenex™) which was protected with a C l 8 Phenomenex™ guard cartridge. The
mobile phase consisted of an isocratic mixture of acetonitrile 85%, MeOH 15% with 1 ml
triethylamine per liter of mobile phase added to inhibit degradation of the carotenoids on
column. The flow rate was 1.0 ml/min. The injection volume was 20 pi. The
chromatograms of pre- and post- reduction reaction were shown in Figure 7 and Figure 8 .

(ii) Reduction of separated compounds A and B with NaBH 4
Carotenoids were extracted from 2 ml serum according to the procedure described
above. The carotenoid extracts were analyzed using the reversed phase HPLC system (1).
The separated compounds A and B were carefully collected into two 2 ml vials. After a
number of injections, the collected compounds A and B were dried under a stream of
nitrogen gas. Since the retention times of compounds A and B are very close, further
purification was carried out by adding

2 0

pi of ethanol to the dried samples which were

re-separated using the same HPLC system. Chromatograms obtained for the re-injection
analysis of compounds A and B are shown in Figure 9 and 10, respectively. It can be seen
that there is a small shoulder (Figure 9) resulting from a trace of compound B in the
purified sample of compound A. Similarly, the small peak (Figure 10) eluting prior to
compound B is a trace of compound A and the small shoulder with a longer elution time
is lutein. Compounds A and B were separately collected into 2 ml vials, then dried with a
stream of nitrogen gas. Reduction reactions were carried out for both compound A and B
following the procedure described above. After reduction, both samples were analyzed by
reversed-phase HPLC system as above and the products of the reactions were collected
and dried. Typical chromatograms obtained for the reduced A and B are shown in Figure
11 and 12. These reduced compounds were also co-injected with the lutein/zeaxanthin
(1:1) standard and the results are shown in Figure 13, 14 and 15.
(iii) Comparisons of UV absorption Spectrum
The extracted carotenoids from 2 ml serum were analyzed by the reversed-phase
HPLC system (2) with a 250ml injection loop and followed by a Shimadzu SPD-M 6 A
photodiode array UV/Vis detector. In order to obtain a good quality spectrum, a 250x10.0

mm Ultracarb 3 pm ODS column was used. The carotenoids extracted from 2 ml serum
can be totally introduced to the column in one injection using this setup. The flow rate
was 4.0 ml/min. and a typical chromatogram for the carotenoid analysis is shown in
Figure 16. Compounds A and B are well separated and were collected separately. The
UV absorption spectrum of lutein, compound A and B were obtained and are shown as in
Figures 17, 18, and 19. The collected compounds A and B were subjected to reduction
following the previously described procedures. After reaction, the products were
analyzed using the same HPLC/UV/Vis system. The absorption spectra were recorded
over the wavelength range of 195-600 nm.
3.

Results and Discussion
As mentioned before, peaks A and B were two unknown components. They eluted

before lutein on a reversed-phase HPLC. (Figure 7) Both compounds A and B were
thought to be the oxidative metabolites of the hydroxy-carotenoids. One or two carbonyl
groups may be present on the ionene end-rings. Lutein is the most abundant hydroxycarotenoid found in human blood. It has been suggested that lutein functions as an
antioxidant. If this is true, mono- or di-keto forms of lutein are expected to be found in
serum. Figures 5 and

6

show several of the possible mono- or di-keto oxidative

metabolites of lutein. The suspected carbonyl on the compounds A and B, if present,
should be reduced by NaBH 4 to produce a hydroxyl group. The structures of reduced A
and B might be expected to be that of lutein or lutein stereoisomers. In this study, three
experiments were designed to test this hypothesis.
In the experiment Reduction of serum extract with NaBH4, the serum extract
was directly reduced with NaBH 4 and the products were reanalyzed and compared with

the serum extract obtained prior to reduction. It was found that the peak height of
compounds A and B decreased significantly after the reduction reaction. (Figure 8)
However, no significant increase in the peak area of lutein can be observed because of the
low concentration of A and B in comparison to the concentration of lutein in the extract.
The changes in peak area ratios, which result from reduction of A and B, are shown in
Table. 1. Lutein is stable toward the treatment by NaBH4. The increases of peak ratios for
both A and B indicate that both compounds react with NaBH4. The result of this
experiment is consistent with the presence of a carbonyl group in both compounds A and
B.

Before Reduction

After Reduction

Lutein peak area/Peak A area

10.30

54.17

43.87

Lutein peak area/Peak B area

12.01

97.05

85.04

Table 1.

Changes in Ratio

Changes in peak ratio of Lutein peak /A and Lutein peak /B

In order to further characterize these two unknown compounds, Reduction of the
separated compounds A and B with NaBH4 was conducted. Because the retention
times of lutein and these two compounds are very close, separation and collection was
done twice in order to obtain pure samples. (Figures 9 and 10) Reduction reactions were
performed for both separated A and B. For compound A, two peaks, Ai and A 2 , were
observed on the HPLC chromatogram after reduction at retention times of 9.116 and
10.366 minutes, respectively. (Figure 11) An additional peak of variable height was

observed at about 19 min. Since peak Ai has the same retention time as Peak A, its
identity was consistent with some unreacted compound A. Peak A 2 was collected and co
injected with a lutein/zeaxanthin standard (1:1). There was not an observable increase in
the peak area of the lutein peak. (Figure 14) However, a small peak was observed at
retention times of 10.483min, which is the time of B elution in the chromatogram, where
no peak can be found in the chromatogram of the lutein/zeaxanthin ( 1 : 1 ) standard.
(Figure 13)
There are three peaks labeled Bi, B 2 , B 3 and an unknown peak that can be
observed in the chromatogram obtained by reduction of product B at retention times of
9.725, 10.316, 11.075 and 20.658 min, respectively (Figure 12). Bi was considered as the
impurity of compound A and B 2 was unreacted compound B. Peak B 3 has same retention
time as lutein, peak B 3 was collected and co-injected to the lutein/zeaxanthin ( 1 : 1 )
standard and a significant increase in peak high of the lutein peak was observed. (Figure
15) These results are consistent with the identity of component B as an oxidative product
of lutein possessing a carbonyl group. After reduction reaction, B was in part reduced to
form lutein.
In order to prove the result obtained from the above experiment, com parisons of
UV absorption spectra were performed. Figure 16 to Figure 27 show the results. The
spectrum of peak B 3 is identical to the UV absorption spectrum of an authentic lutein
standard. (Figure 17 and Figure 22) Spectra of A and B are shown in Figure 18 and
Figure 19. They are lutein-like, but the Xmax of A is 5 nm shorter than that of lutein. The
keto groups in the oxidative products of lutein are expected to be on C3’ of the s-end
ring. These carbonyls are not expected to be conjugated with the extended polyene

system. Therefore, reduction of these keto groups has little or no effect on the absorption
spectra of the compounds. In other words, they should have similar spectra to lutein. Co
injection was also performed in this part of the experiment. The results agree with those
obtained above. Peak B 3 caused a significant increase in lutein peak. (Figure 25) The
same result was obtained from the co-injection of reduced compound A with the
lutein/zeaxanthin (1:1) standard. (Figure 23) There is only a marginal increase in peak
area observed, (Figure 24) but this may be only because the amount of material is small.
An unexpected result was obtained in this study. An unknown peak was found in
both chromatograms of reduced compounds A and B. (Figure 11, 12, 20 and 21) The
retention time of this unknown is about 19-20 min which is near the time of |3cryptoxanthin elution in the chromatogram of serum analysis. (Figure 7) A side reaction
might occur during the reduction process. The spectrum of this unknown peak from both
reduced compounds A and B was also obtained and is shown in Figures 26 and 27. These
spectra are both similar. Since an authentic standard of p-cryptoxanthin is not available,
the further comparison was not pursued. It appears to be a single compound produced
from both A and B.
4.

Conclusion
The UV absorption spectra of authentic lutein, compound A and B are shown in

Figure 17, 18 and 19. The UV absorption spectrum of compound B is identical as that of
authentic lutein. Compound A has unique spectroscopic with Xmax 5 nm shorter than that
of the lutein. The two unknown compounds A and B both react with NaBIU. They appear
to be oxidized carotenoids containing one or more carbonyl function groups. B is reduced

to form lutein. Compound B might be either the mono- or diketo- form of lutein.
Characterization of compound A has proven difficult.
A comparison experiment, oxidization of lutein, would be very helpful for further
identification and this project is currently in progress. The structures of lutein oxidation
products can be identified by NMR since sufficient quantities can be readily prepared.
LC-MS will also be essential for final identification of these compounds. This technique
was not available during this study but is also currently under way.
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Figure 9. Purified lutein metabolite A
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Figure 10. Purified lutein metabolite B
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Figure 13. HPLC chromatogram of lutein/zeaxanthin (1:1) standard
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Figure 17. UV/Vis spectrum of authentic lutein, Xmax=446 nm
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Figure 18. UV/Vis spectrum of lutein metabolite A, /.max=441 nm
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Figure 19. UV/Vis Spectrum of lutein metabolite B, A.max=446 nm
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Figure 20. HPLC chromatogram of reduced lutein metabolite A on
a 10.00 mm C18 column
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Figure 21. HPLC chromatogram of lutein metabolite B on
a 10.00 mm C l8 column
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Figure 22. UV/Vis spectrum of B3 A.max=450 nm
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Figure 24. HPLC chromatogram of co-injection A2 with
lutein/zeaxanthin (1:1) standard on a 10.00 mm
C l8 column

lutein/zeaxanthin (1:1) standard on a 10.00 mm
C l 8 column
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Figure 26. UV/Vis spectrum of unknown peak from the chromatogram
of reduced lutein metabolite A, kmax=452 nm
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Figure 27. UV/Vis spectrum of unknown peak from the chromatogram
o f reduced lutein metabolite B, >umax=456 nm
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PART 2

1.

Overview

ZEAXANTHIN SUPPLEMENTATION STUDY

Zeaxanthin is a yellow pigment that is widespread in nature. It occurs abundantly
in maize, certain algae and bacteria. Zeaxanthin is 6 , 6-carotene-3, 3’-diol (Figure 1). It
is found in human serum. Although it is not the most abundant carotenoid in serum, it is a
main component of macular pigment in the inner macula where the concentration of
zeaxanthin is about twice that of lutein. (Bone, et al., 1997) The macular pigment has a
protective function for the central retina. It has been reported that a significant increase in
macular pigment optical density occurs when dietary supplements increase serum
xanthophyll levels. (Landrum, et al., 1997) In this study, we have found the relationship
of the serum response to dietary supplementation of zeaxanthin.
Among the number of methods that have been employed to investigate the
absorption of carotenoids in humans, the most common one is the chronic dosing of a
carotenoid and the measurement of the blood response. (Bowen, et al., 1993) The
carotenoid may be in the form of a purified compound or ingested as a food. Healthy
human subjects are given quantitated amounts of carotenoids, and changes in serum
concentrations at various time intervals are determined. This method does not provide the
absolute quantity or percent of the carotenoid absorbed. Some other methods of choice
are metabolic balance techniques using isotopically labeled carotenoids. The metabolic
balance technique involves the estimation of total carotenoid intake for a period of days
called the balance period and the collection and analysis of all fecal output for
carotenoids for the same time period. Output is subtracted from input and divided by the

number of days of the balance period to obtain the quantity of carotenoid absorbed in the
body per day. These methods are complicated. They do provide more definitive data for
the characterization and quantitation of carotenoid absorption in human. The method of
chronic dosing and measurement of serum response has been employed in this
experiment. The concentrations of carotenoids in the serum were measured using
reversed-phase HPLC.
2.

Experimental

(1) Reagents and materials
HPLC grade Methanol, Acetonitrile, Hexane and Ethanol were purchased from
Fisher. Pure lutein was obtained from Kemin Foods, Inc.
(2) Apparatus
Reversed-phase HPLC system (1) is a Waters 2690 separation module coupled
with a Waters 486 tunable absorbance UV/Vis detector.
Reversed-phase HPLC system (2) is an LDC Analytical Consta Metric 3200
solvent delivery system equipped with a 250 pi injection loop and coupled with an
LDC/Milton Roy UV detector.
(3) Procedures
One healthy, male, non-smoker volunteer supplemented his diet with 30 mg of
zeaxanthin per day for 120 days. Blood samples were drawn every two days in the
beginning of the supplementation period and also at the end of that period. At other
times, blood samples were drawn weekly. The concentration of zeaxanthin in the serum
before supplementation was also measured as a baseline level. All serum samples were
analyzed by reversed-phase HPLC. An internal standard, mono-hexyl lutein (MHL), was

used to quantify carotenoids. The concentrations of zeaxanthin and other carotenoids
were determined from the peak area of the internal standard since the quantity of the
internal standard is known. It has been previously shown that both the internal standard
and lutein have the same absorption coefficient. (Sprague, 1997) The relative differences
in absorption were determined by comparing the serum carotenoids concentration at
various post-ingestion intervals with the baseline values.
(i) Sample preparation
Blood was drawn into a 5 ml Vacutainer serum-separator tube by venipuncture.
After allowing at least 30 min for coagulation, the blood samples were centrifuged for 10
min and the serum portion was removed by a disposable pipette and placed into highdensity polypropylene 2 ml vials which are fitted with a rubber O-ring seal. Serum was
filled to the capacity to minimize any potential oxidation by air. Samples were analyzed
immediately or stored at -20°C in the dark to minimize degradation.
(ii) Serum extraction
A 200 pi aliquot of serum was transferred into a centrifuge tube by a pipette. 20
pi of mono-hexyl lutein was added to this portion of serum as an internal standard. The
concentration of the internal standard was 56.81 ng per 20 pi. The serum proteins were
precipitated by the addition of 2 ml of ethanol/deionized water (50:50, V:V). The
carotenoids were extracted with three

2

ml portions of hexane, and followed by a

1

min

vortex and 5 min centrifugation. The hexane layer was removed by pipette into a highdensity polypropylene vial and evaporated to dryness under a stream of nitrogen. All the
procedures were preformed carefully in a dim light condition. The extracted carotenoid
sample was dissolved in 50 pi of ethanol for HPLC analysis, or the dried extracted

carotenoid sample was stored in the dark -20°C prior to HPLC analysis. To minimize
experimental errors, two replicate extracted carotenoid samples were prepared from each
serum sample and two analyses were made for each by injecting two aliquots from each
extraction. The average concentrations of the carotenoids were calculated from the four
injections.
(iii) Preparation of MHL internal standard
The internal standard was chosen because of its chemical similarity to that of the
analyte. It was previously shown that the internal standard and the analytes would have
same percent recovery in the process of extraction and would behave similarly on the
HPLC column. Both assumptions have been proved in a previous study in our group.
Mono-hexyl lutein (MHL) was chosen as an internal standard for quantitative analysis of
extracted carotenoids from serum in this experiment. It was synthesized as follows:
An acidified hexanol solution was prepared by adding 10 pi concentrated HC1 to
10 ml hexanol. About lm g of dry lutein (Kemin Foods, Inc.) was dissolved in this
acidified alcohol solution. The mixture was stored at 4 °C for at least 24 hrs to allow the
reaction to reach completion. The structure of MHL is shown in Figure 28. Fifty ml of
saturated NaHCC >3 solution was transferred to the mixture to quench the reaction. The
carotenoids were extracted with equal portions of CH 2 CI2 . The CH 2 CI2 was evaporated
by a rotary evaporator. The dried MHL was dissolved in ethanol and purified by a
reversed-phase HPLC system (2)(LDC/Milton Roy solvent delivery system) which
coupled with an SM4000 UV-Visible detector set at 451 nm. A manual injector with a
250 pi injection loop was installed in this HPLC system. The column used was a 250x4.6
mm Ultracarb C18 3pm ODS (Phenomenex™). The flow rate was 1.0 ml/min. The

mobile phase used was 85%

acetonitrile,

15% methanol, with 0.1%

(V:V) of

triethylam ine added. The M HL peak was collected at a retention time of 40 min and dried
under a stream o f nitrogen gas. The dried M H L was re-dissolved in ethanol. The
concentration of M H L was determ ined by the absorption at a wavelength of 451 nm. The
absorption coefficient o f M H L is considered the same as lutein which is 250 Lg 'c m 1.

(iv) R eversed-phase H PL C conditions
Analysis o f all extracted carotenoids from serum samples were conducted on a
W aters 2690 separation m odule HPLC with a W aters 486 UV tunable detector set at 451
nm. The data was stored and processed on the M illenium integration software. The
colum n used was a 250 x 4.6 mm C l 8 column packed with 3 pm Ultracarb ODS
(Phenom enex, Torrance, CA, U.S.A) and was protected with a C18 Phenomenex™ guard
cartridge. Separation was achieved with a mobile phase of 85% acetonitrile and 15%
methaol, with 0.1% (V/V) of triethylamine added to inhibit degradation of carotenoids
during elution. The flow rate was 1.0 ml/ min.

3.

R esults and Discussion
The concentration of the carotenoids in serum are reported in pg/ml. The

calculation is based on B eer’s law

A = ebC

(1)

W here A is absorption, e is m olar extinction coefficient, b is the pathlength of the cell,
and C isthe concentration of the analyte. The £ value is the same for allanalytes as well
as the internal standard MHL. Therefore,
C

a=

(A

a

*C

m hl) / A m hl

W here C A is the concentration of the carotenoids.

(2 )

Cm hl

is the concentration of the

internal standard, M HL. A a is the peak area of the carotenoid obtained from the
chrom atogram .

A Mh l

is the peak area of the internal standard, MHL.

The concentration of zeaxanthin in the serum is plotted as a function of time as
shown in Figure 29. It represents the average concentration of zeaxanthin of four
replicate analyses vs the day of the supplementation. The first day of the supplementation
is counted as zero.

Figure 29. Plots o f serum zeaxanthin concentration as a function of time, (a)
represents the best fit during the supplem entation, (b) represents the
best fit after discontinue the supplementation.

It can be seen that there is a significant increase of serum zeaxanthin during the
first 40 days of supplementation. A plateau of about 0.30 pg/ml was maintained between
the day 40-120 supplementation period. It was also found that the concentration dropped
rapidly to the baseline level once the supplementation was discontinued. Although small
changes were found in the concentration of zeaxanthin

inserum

due tothe dietary

sources, the effect of diet on this experiment is smallbecause of the high dosage (30 mg
per day) of zeaxanthin taken by the subject.
A baseline zeaxanthin concentration C 0 was calculated from the average
zeaxanthin concentration of pre-supplement analyses. The uptake and decay of
zeaxanthin concentration in serum as a function of time were fit using equation ( 3 ) and
(4), respectively. Those two equations have been also used to fit the experiment data in a
previous long-term lutein supplementation study.
C = C 0 + a ( 1 - e'kl)

(3)

C = C 0 + b e -k <‘" V(

(4)

Where C is the experimentally determined concentration, t is the time, tf is equal
to

1 2 0

days which is the first day when the subject discontinued the supplement, a, b, k,

and k ’ are parameters varied to obtain the best fit. These fit parameters are found in table

2.
PARAMETERS
a
b
k
k’

ZEAXANTHIN

METABOLITE A

METABOLITE B

METABOLITE C

0.269
0.029
0.071
0.0566

0.0038

0.0062
0.052
0.054
0.073

0.078

0.067

0 .1 1

0.041
0.053

Table 2. parameters for uptake and decay of zeaxanthin supplement and metabolite serum
concentrations.

D uring the supplementation, the metabolites of zeaxanthin were also determined.
Their concentrations were calculated using the same method as that of zeaxanthin. Figure
30 (a) and (b) show the chromatogram s of serum extract before and after 40 days
supplem entation.

extract prior supplem entation (a) H PLC chrom atogram
o f carotenoids from serum extract after 40 days
supplem entation w ith 30 m g/day zeaxanthin

Peaks A, B and C represent the xanthophyll metabolites that are observed in
serum. C om pound C has been characterized as a c/s-isom er of zeaxanthin. It was found
that both peak B and C increased significantly after supplem entation with zeaxanthin.
Figures 31, 32 and 33 represent the average concentrations of these metabolites vs the
days of the supplem entation. The results show that metabolites B and C increase rapidly
from the baseline levels of 0.03, and 0.008 pg/m l to a plateau that is about three and ten
times

higher, respectively, than the baseline level prior to

the first 40

days

supplementation. The concentrations of both B and C dropped to the baseline level once
the supplementation was discontinued. The average concentration of metabolite A did not
change during zeaxanthin supplementation. It maintains an average concentration of
0.016 pg/ml. This result supports those obtained previously that suggest A to be a lutein
metabolite. The changes in the average concentrations of zeaxanthin metabolites A , B
and C are listed in table 3.
Average concentration (Standard Deviation)

Baseline Level

Plateau Level

Zeaxanthin

0.055 (±0.007)

0.324 (±0.053)

Metabolite A

0.016 (±0.003)

0.016 (±0 .0 0 2 )

Metabolite B

0.03 (±0.003)

0.08 (±0.007)

Metabolite C

0.008 (±0.0003)

0.077 (±0.006)

Table 3. Serum average concentration and standard deviation of zeaxanthin and
the metabolites A, B and C

The calculated half-lives for the uptake and decay of zeaxanthin and metabolites,
and the half-lives of lutein obtained from a previous experiment are listed in table 4.
HALF-LIVES

LUTEIN

ZEAXANTHIN

METABOLITE B

METABOLITE C

ti/ 2 uptake

9.6

9.76

12.83

16.90

1 1/2decay

8.13

12.24

9.49

13.08

Table 4. The calculated half-lives for the uptake and decay of the concentrations of lutein,
zeaxanthin and metabolites B and C.

4.

Conclusion
The concentration of zeaxanthin as well as the metabolites B and C in

human serum is increased by zeaxanthin supplementation during the first 40 days of
supplem entation. Plateaus maintained

concentrations of 0.32, 0.079, and 0.077 pg/ml

between days 40 - 120 of supplem entation for zeaxanthin and m etabolites B and C,
respectively. The concentrations dropped to the baseline level once the supplement was
discontinued.

No

correlation

was

found

for

metabolite

A

during

zeaxanthin

supplem entation.

of time.

Figure 32. The plot of serum concentration of m etabolite B as a function
o f time.

Figure 33. The plot of serum concentration of m etabolite C as a function
o f time.
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PART 3

A SIX MONTH STUDY OF LUTEIN UPTAKE IN 22

HUMAN SUBJECTS

1.

Overview
Lutein, as a micronutrient, has been found in many fruits and vegetables that we

consume. It is also one of the most abundant carotenoids found in the human body. It acts
as an antioxidant. The structure of lutein is shown in Figure 1.
As an antioxidant nutrient, lutein is normally accumulated in the macula region of
the human retina. The macula is the anatomical region of the retina that is responsible for
central vision. It is composed of several functionally and structurally distinct layers
overlaying and supporting the cone and rod photoreceptors. Lutein and zeaxanthin are the
major constituents of human macular pigment. (Bone, et al., 1985). Macular lutein is
believed to function as a blue light filter by absorption of blue light. The macular
carotenoids can reduce the blue light intensity reaching photoreceptors on average by
about 40 percent. (Landrum, et al., 1996) Blue light can cause the formation of singlet
oxygen, triplet excited state species, and free radicals. Lutein may act as an active
quencher of singlet oxygen, and excited state triplets. It can react with and deactivate
radical species preventing chain propagation. These actions may all be functions of
carotenoids of the macular pigment.
Age - related macular degenaration (AMD) is one of the eye diseases which
disrupts the normal functioning of the macula. It occurs in about 20% of people over the
age of 65. (Landrum, et al., 1995; Landrum, et al., 1997) It is an irreversible condition of

a visual impaiment. There are many factors with the positive correlation with AMD. The
low levels of dietary xanthophylis and serum xanthophylis are two factors among them.
Landrum, et a l, (1995) have reported that lower than normal amounts of macular
pigment are found in person with AMD. The macular pigment may reduce the risk of the
AMD. (Hyman, 1992, Eye Disease Case-Control Study Group, 1993, Seddon, et a l,
1994) In Landrum’s early study, it is reported that the amount of the macular pigment
may be enhanced by dietary supplementation with 30 mg of lutein per day. (Landrum, et
a l, 1997) It is known that the average optical density of the macular pigment in the retina
is proportional to the average pigment concentration. (Handelman, et a l, 1991) The
optical density can be measured by heterochromatic flicker photometry. It was
established that the macular pigment optical density increased in the eyes when the
concentration of lutein was elevated in the serum during a long-term supplementation
study with a lutein ester form supplement. (Landrum, et al 1997) It was found that the
concentration of lutein in serum decreased and returned to pre-supplementation levels
after the subjects discontinued the supplement. However, the optical density remained
higher than the pre-supplementation level after conclusion of supplementation and did
not return to baseline. Therefore, the hypothesis that lower doses of lutein might also
cause similar increases in macular pigment optical density in eyes was suggested. This
study, based on the earlier methods, used a large group of subjects
order to determine if low dosages produced a significant result.

(2 2

human subjects) in

2.

Experimental

(1) Reagents and materials
HPLC grade Methanol, Acetonitrile, Hexane and Ethanol were purchased from
Fisher. Nitrogen gas was purchased from Air Products and Chemicals, Inc.
A 250x4.6 mm column Ultracarb C l 8 3pm ODS and a guard column were from
the Phenomenex, Torrance, CA, U.S.A.
(2) Apparatus
The reversed phase HPLC was a Waters 2690 separation module equipped with a
column heater and a sample cooling system. A Waters 486 tunable absorbance UV/Vis
detector was used for detection.
A heterochromatic flicker photometer was constructed as previously described.
(Bone, et al., 1971, Bone, et al., 1992)
(3) Procedures
In this study, 22 healthy, non-smoker human volunteers were selected. None of
the subjects took a commercial dietary supplement that included carotenoids during the
period of time of this study. Eye exams were performed by an ophthalmologist before
supplementation for each subject. For several subjects a follow-up eye exam was also
performed. These 22 volunteers supplemented their diets with lutein (1.2 mg x 2 per
day), in the form of Nutrilite’s softgel Bilberry with Lutein Botanical Blend for a period
of six months. Blood samples were drawn weekly from the subjects and analyzed by
reversed-phase

HPLC.

The

initial

baseline

of serum

lutein

level

and

post

supplementation serum lutein level were monitored for the subjects. The same
experimental method as previously described was conducted. The macular pigment

optical density for the subjects was measured twice each week by heterochromatic flicker
photometry to determine both pre- and post- optical density levels in their eyes.
(i) Serum sampling and handling
Blood was sampled into 5 ml Vacutainer serum separator tubes by venipuncture.
Serum was separated from blood and stored in the freezer by the same procedures as
described in part 2. Serum samples were labeled to identify the subjects and the day the
blood was sampled.
(ii) Serum extraction
Serum extraction was preformed by following the same procedures as in part 2.
A 200 pi aliquot of serum was taken for the extraction from each serum sample. 20 pi of
monhexyl lutein (MHL) was added to this portion of serum as an internal standard. The
amount of the internal standard was about 50 ng. The extracted sample was dissolved in a
50 pi of ethanol for HPLC analysis, or the dried extracted sample was stored in the dark
at -20°C until HPLC analysis. A replicate injection was preformed for the each extraction
in order to minimize the experimental errors.
(iii) HPLC conditions
All serum samples were analyzed on a Waters 2690 module HPLC with a Waters
486 UV tunable detector set at 451 nm. The data were stored and processed on Millenium
intergration software. The column used was a 250 x 4.6 mm C l 8 column with a C18
guard column packed with 3 pm Ultracarb ODS. The column was housed in a column
heater set at 25°C. A sample cooling system was installed in this HPLC and it was set to
4°C to minimize potential sample degradation. Separation was achieved with a mobile

phase of 80% acetonitrile and 20% of methaol, with 0.1% (V/V) of triethylamine added
to inhibit degradation of carotenoids during elution. The flow rate was 1.0 ml/ min.
3.

Results and discussion
The pre- and post- supplementation serum lutein levels and macular pigment

optical densities of the subjects are shown in Table 5. The baseline serum lutein
concentrations and macular pigment optical densities were measured as the mean value of
all measurements during the period of time of pre- supplementation. The first day of
supplementation was counted as zero. The post- supplementation serum lutein
concentrations and macular optical densities were the mean value of all measurements
taken between day 7 and day 150 of supplementation. For the subjects who dropped-out
from the study prior to day 150, the mean concentration and macular pigment optical
densities were calculated from all data after day 7. It was observed that there was a
significant increase in serum lutein concentration for all subjects. The percentage increase
ranged from 20% to 300% with a mean increase of 128% (median = 116%). The increase
in macular pigment optical density was significant for 11 of the 19 subjects. The mean
increase for all 19 subjects was also significant as 4.5%.
Baseline dietary intake for lutein and zeaxanthin of 1.2 ±1.1 mg/day was
determined from a food frequency questionnaire. Therefore, the 2.4 mg of dosage
represents about twice the mean dietary intake. Figure 34 shows the plot of pre
supplement serum lutein level vs dietary intake. A significant correlation was found
showing that the higher the dietary intake the higher the supplementation level of pre
serum lutein. We also note that individuals with high pre-supplementation serum lutein
levels also had high post-supplementation levels (Figure35). Figure 36 (a) and (b)

represent two typical examples from the two subjects with different pre- supplementation
serum lutein levels. Subject B has higher pre- and post- supplementation serum lutein
levels than that o f subject A.

M acular Pigm ent O ptical Density

Serum Lutein (pg/ml)
Subject
n u m b er
1
2

3
4
5
6

7
8

9
1 0
1 1
1 2

13
14
15
16
17
18
19
2 0
2 1

Average

Pre
supplem ent

Post
supplement

% increase

Absolute
increase

Pre
supplement

Post
supplement

0.092
0.187
0.104
0.091
0.076
0.163
0.257
0.058
0.188
0.062
0.059
0.141
0.148
0.163
0.250
0.089
0.203
0.208
0.080
0.240
0.060

0.137
0.384
0.275
0.284
0.148
0.382
0.339
0.132
0.336
0.179
0.231
0.459
0.307
0.292
0.311

49
106
165

0.045
0.197
0.171
0.192
0.072
0.218
0.082
0.074
0.148
0.117
0.172
0.317
0.159
0.129
0.061

0.415
0.448
0.678
0.28
0.397
0.315
0.81
0.243

0.426
0.495
0.695
0.4
0.413
0.338
0.83
0.252
0.61
0.219
0.311
0.65
0.487
0.514

0 .2 1 0

0.275
0.469
0.340
0.280
0 .2 0 2

2 1 1

95
134
32
127
79
189
291
225
107
79
25
136
35
126
325
17
235
128

0 .1 2 1

0.071
0.261
0.260
0.040
0.142

0 .6

0.205
0.311
0.612
0.384
0.45
0.387
0.613
0.465
0.307
0.186
0.711
0.478

0.706
0.489
0.388
0.318
0.719
0.528

%increase

Absolute
increase

2 .8

0 .0 1 1

10.5
2.5
40
4.2
7.5

0.047
0.017
0.016
0.023

2

0 .0 2

3.7

0.009

0 .1 2

1

0 .0 1

6 .8

0.014

0

0

6 .1

27
14
15
5
26
71
1

10.3
4.5

0.038
0.103
0.064
0.093
0.024
0.081
0.132
0.008
0.05

Table 5. Pre- and post- supplem entation serum lutein levels and macular pigment
optical densities o f the subjects

W e can see that one of the m etabolites, labeled as peak A, increased significantly
during the supplem entation. (Figure7) Table 6 shows average % increases in several
serum carotenoid levels. Some variation of serum carotenoid levels occured during the
period of time of supplem entation since the subjects were on an uncontrolled diet. Peak A

is the only significant change other than lutein in the chromatogram. This agrees with the
results of the high dosage lutein supplementation study and gives further evidence that A
is the metabolite of lutein. However, B and C only had little increases. We noted that
different forms of lutein supplement have been taken in this and previous studies. Instead
of a form of supplement containing natural free lutein, a commercial available
supplement form was giving. It is understandable that the different form of the
supplement should affect the presence of the metabolites.

% Average increase
Lutein

128

Macular Pigment Optical Density

1 2 .8

Peak A

1 0 1 .2

Peak B

24.3

Peak C

36.4

Zeaxanthin

12.9

P-Cryptoxanthin

3.6

Table 6 . Percent average increases from all human subjects in several carotenoids,
metabolites and optical density after supplementation

4.

Conclusion

This study has shown that supplementation of the normal diet with as little as 2.4 mg/day
of lutein results in increased serum levels of lutein by as much as 300% in some
individuals and results in a increase in macular pigment optical density for 19 of the
study group. We also noted that the serum levels of several metabolites also have
increases. A correlation between pre-supplementation and post-supplementation was also

found. The higher the pre-supplem entation level the higher the post-supplementation
level of serum lutein.
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Figure 35. Plot of pre-supplem entation serum lutein concentration vs post
supplem entation serum lutein concentration

0.300

Figure 36. The plots of serum concentration of lutein as function of time from two human
subjects (a) and (b) with low er and higher pre-supplem entation serum lutein
levels.

IV
PA R T 4
SAM PLES

1.

ZEAXANTHIN STER EO ISO M ERS IN HUMAN SERUM

Overview
Zeaxanthin is one of the carotenoids found in the human body. It has two stereo

centers in the positions o f C3 and C 3 ’ which give rise to three stereoisomers, (3R,3’R)P,P-carotene-3,3’-diol, (3R ,3’S)-p,f3-carotene-3,3’-diol and (3S,3’S)-|3,p-carotene-3,3’diol. The structures of these three stereoisomers are illustrated in Figure 37.

Figure 37.

S t e r e o c h e m i c a l s tr uctu re s of z e a x a n th i n

As mentioned earlier, lutein and zeaxanthin are major components of macular
pigment in the human retina. (Bone, et a l, 1988) The macular pigments play a protective
role in the eye. The concentration of zeaxanthin is about twice that of lutein in the inner
macula. (Bone, et a l,

1988) The macula contains the highest density of cone

photoreceptors and is specialized for acute central vision. The macula is visually
pigmented with the yellow carotenoids. The yellow spot is about 2 to 3 mm in diameter
in human eyes. The macula is divided into the inner macula and the outer macula. The
inner macula is about 1.5 mm in diameter and the outer macula is the surrounding
annulus. Figure 38 shows the human eye in cross-section. As eccentricity from the fovea
increases, the lutein/zeaxanthin ratio of concentrations continuously changes with lutein
becoming the dominant component. It was reported that all three zeaxanthin
stereoisomers (RR, RS, SS) are present in the human eye. (Landrum, et a l, 1999; Bone,
et al., 1997) The concentration of RS zeaxanthin decreases with eccentricity. This
decrease in RS zeaxanthin closely corresponds to the increase in lutein. (Landrum, et al,
1999; Bone, et a l,

1997) Among the three zeaxanthin stereoisomers, the RR

configuration is the only one that is found in significant quantities in the diet and is
relatively abundant in a number of fruits and com. Since animals cannot synthesize
carotenoids, RR-zeaxanthin would be expected to be the sole stereoismer to be found in
human body. The presence of RS and SS zeaxanthin in the retina suggests that the
conversion of lutein to zeaxanthin may occur by migration of a double bond in the lutein
molecule. Landrum et al have reported that only RR-zeaxanthin has been detected in
human blood. (Landrum, et a l, 1999) Therefore, the process of conversion would seem

to occur in the eye. The purpose of this study was to confirm the absence of RS and SS
zeaxanthin in human serum. The composition of zeaxanthin stereoisomers in serum

Figure 38. Cross-sectional diagram of the human eye. (Handelman, 1992)

samples from 18 subjects was studied by normal phase HPLC.

2.

E xperim ental

(1) Reagents and m aterials
HPLC grade M ethanol, Acetonitrile, Hexane, Ethanol, and Isopropyl acetate were
purchased from Fisher. Pyridine anhydrous 99% (water<0.005% ), benzene (99.8%
anhydrous), and (S )-(+ )-l-(l-N aphthyl) ethyl isocyanate were purchased from Aldrich
Chem ical Company. (M ilw aukee W I 53233 USA) Synthesized, pure RR, RS, and SS
zeaxanthin were obtained as a gift from the com pany Hoffman La Roche.
A 250x2.Omm normal phase column packed with 5pm Prodigy silica and a
250x10.0 m m reversed phase column packed with 3pm Ultracarb ODS were purchased
from Phenom enex, Torrance CA. U.S.A.

(2 ) Apparatus
Reversed phase HPLC system (1) was an LDC Analytica Consta Metric 3200
solvent delivery system equipped with a 50 pi injection loop and was coupled with an
LDC/Milton Roy UV detector. Normal phase HPLC, system (2), was an LDC Milton
Roy system which included an SM4000 UV/Vis detector.
(3) Procedures
Serum samples were obtained from 20 human subjects. 2 ml of serum from each
subject was extracted. In order to isolate the zeaxanthin from each sample, reversedphase HPLC system (1) was employed. This included a 250x10.0 mm C18 column.
Zeaxanthin was collected during elution and dried under a stream of nitrogen gas. The
dicarbamate derivatization reaction was carried out individually on the collected
zeaxanthin for each subject’s sample. The dicarbamate derivatives of the collected
zeaxanthin were further analyzed by normal phase HPLC, system (2), to determine the
stereoisomer composition. The separated stereoisomer peaks were collected and dried for
further identification analysis. For comparison purposes, a racemic standard of the three
synthesized zeaxanthin stereoisomer mixtures was converted to the dicarbamate
derivatives. The concentration ratio of these three stereoisomers, RR:RS:SS, was equal to
1:2:1. The identification of zeaxanthin stereoisomers in 20 human subjects was
determined from the peak enhancement by the co-injection of the collected, derivatized
stereoisomer components with the racemic mixture of zeaxanthin dicarbamates.
(i) Preparation of standard
Three

synthetic

zeaxanthin

steroisomers,

(3R,3’R)-p,p-carotene-3,3’-diol,

(3R,3’S)-p,p-carotene-3,3’-diol and (3S,3’S)-p,p-carotene-3,3’-diol, were obtained as a

gift from the company Hoffman-La Roche. They were separately dissolved in EtOH in
three pear-shaped flasks. Since the absorption coefficients of these three stereoisomers
are identical, the concentration ratio (RR:RS:SS) was determined from UV spectrometry.
The three stereoisomers were mixed together to produce a

concentration ratio of

RR.RS:SS equal to 1:2:1. This racemic-mixture of steroisomers was dried under a stream
of nitrogen gas. The dicarbamate derivatization reaction was carried out under nitrogen
gas in a glove box following the derivatization procedures described below.
(ii) Carotenoids extraction and zeaxanthin collection
2

ml of serum from each subject was extracted individually by following the

extraction procedures mentioned previously. The extracted carotenoids were dissolved in
200 pi EtOH for reversed-phase HPLC separation. All carotenoid separations were
conducted on reversed-phase HPLC system (1) with a UV detector set at 451 nm. A C l 8
250x10mm reversed phase column was used for the separation. A mobile phase of 85%
acetonitrile, 15% methanol and with 0.1% triethlyamine was used. The flow rate was 4.0
ml/min. The zeaxanthin peak was collected in a plastic vial, having been identified from
its retention time which was known by running a lutein and zeaxanthin ( 1 : 1 ) standard in
the same HPLC system. The collected zeaxanthin was dried under nitrogen gas for
subsequent derivatization.
(iii) Zeaxanthin dicarbamate derivatization reaction
The plastic vial with the dried zeaxanthin from serum was transferred into a glove
box containing a dry nitrigen atmosphere in order to carry out the derivatization reaction.
The zeaxanthin was dissolved in 50 pi of anhydrous pyridine/benzene (50:50 v/v). 2 pi of

(S)-(-f-)-1-(1 -naphthyl) ethly isocyanate was added to the above solution and the mixture
was capped and centrifuged for 30 sec. The plastic vial was covered with aluminum foil
to exclude light and the mixture was allowed to react for at least 48 hr. Figure 40 shows
the chem ical reaction.

The resulting dicarbam ate derivatives were removed from the glove box. 5 ml of
wet (saturated) hexane was used to rinse the plastic vial and transfer the reaction mixture
to a centrifuge tube. The solution becomes very cloudy. The derivatized zeaxanthin was
extracted by addition o f three 5 ml portions of hexane, followed by 1 min vortex, 5 min
centrifugation. The top clear portion of hexane was removed carefully to a pear-shaped
flask by a syringe and dried under a stream of nitrogen gas.

Since the amount of

zeaxanthin was very small all o f the procedures were carried out very carefully in order
to prevent any loss.

(iv) N orm al phase H PL C separation of zeaxanthin stereoisom ers
The dicarbam ate zeaxanthin derivatives were dissolved in a 20 pi of the mobile
phase and analyzed by a normal phase HPLC (LDC solvent delivery system) coupled

with a UV detector. A 250x2.0mm normal phase column packed with 5 pm silica
(Phenomenex™) was used. The mobile phase was

8 8

% hexane and

1 2

% isopropyl

acetate at a flow rate of 0.2 ml/min. Detection was set at 451 nm.
In order to obtain a good separation, the mobile phase solvent was prepared
freshly since both hexane and isopropyl acetate evaporate rapidly. No internal standard
was used in the analysis since only the relative proportions of the three stereoismers was
sought. The dicarbamate derivatives of the zeaxanthin stereoisomers were compared to
the racemic standard. The peaks were collected and co-injected with the racemic mixture.
Peak enhancement provides a reasonably good confirmation of isomer identification.
3.

Results and discussion
The normal phase HPLC chromatogram of racemic mixture standard is shown in

Figure 40. Three zeaxanthin stereoisomers are well separated. The elution order of the
three zeaxanthin stereoisomers is SS, RS and RR with retention time of 36.11 min, 38.85
min and 42.48 min, respectively. The results of the normal phase separation of the
derivatized macular pigment zeaxanthin isomers from 18 human subjects are presented in
Table 7 and show the percentage of the SS, RS and RR in serum zeaxanthin. It is clear
that RR confirmation is the principal isomer. Figure 41 is a normal phase HPLC
chromatogram from 20 human subjects showing the presence of a major RR peak. This
result supports the hypothesis that the lutein to meso-zeaxanthin

conversion process

occurs in the eye. For further identification, the principal peak was collected and
combined with the racemic mixture. An identical result was obtained for all 18 human
subjects. Figure 42 is a typical example of the co-injection HPLC chromatogram of the
collected stereoisomer peak with the zeaxanthin standard racemic mixture. The observed

enhancement of the all E-R,R-zeaxanthin dicabamate peak provides us the most reliable
conclusion that serum is composed chiefly of this isomer.
SU BJECTS

%SS

%RR

%RS

1

0 .0 0

1.27

98.9

2

1.45

3.95

94.6

3

0 .0 0

3.20

96.7

4

0 .0 0

8.28

91.8

5

1.05

3.42

95.5

6

0.78

5.20

92.8

7

0 .0 0

6.96

93.1

8

0 .0 0

4.09

93.9

9

0 .0 0

11.7

88.4

1 0

0 .0 0

0 .0 0

1 0 0

11

0 .0 0

0 .0 0

1 0 0

1 2

2.67

2.05

95.3

13

0 .0 0

1.24

98.8

14

3.45

2.85

93.7

15

0 .0 0

3.20

96.8

16

0 .0 0

0 .0 0

1 0 0

17

0 .0 0

0 .0 0

1 0 0

18

0 .0 0

0 .0 0

1 0 0

Average %

0.52

3.19

96.3

Table 7. Percentage of zeaxanthin stereoisomers in serum

A small peak can be observed in derivatized zeaxanthin samples of some human
subjects. (Table 5) This is believed to be the RS-zeaxanthin component. The average
percentage of the RS configuration of the total zeaxanthin is about 3%. The SS-

zeaxanthin isom er might be present in some samples based on the presence of a small
peak at the correct elution time. The minute quantities of these potentially RS- and SSprevented confirm ation by co-injection.

4.

Conclusion
A significant difference in zeaxanthin stereoisomer composition between the

serum and the retina was verified in this study. The determination of the composition of
the zeaxanthin stereoisom ers in 18 human subjects was carried out. All-E-RR-zeaxanthin
configuration predom inates in the human serum. The average percentage of the
tentatively identified RS- configuration has been calculated and is 3.37%. However, the
percentage o f tentatively identified SS- confirmation is generally below the detectable
level. The result obtained from this study indicates that the RS and SS zeaxanthin isomers
in the retina are probably form ed by the metabolism of lutein in the retina.
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Figure 40. HPLC chromatogram of dicabamated zeaxanthin
racemic-mixture standard on a Normal phase HPLC

60

Figure 41. HPLC chromatogram of dicarbamated zeaxanthin from
serum extract on a Normal phase HPLC

of dicarbamated zeaxanthin from serum extract with dicarbamated
zeaxanthin racemic-mixture standard on a normal phase HPLC
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